Austin Veterinary Dermatology, Round Rock, TX, USA.
Vet Res Commun. 2010 Jan;34(1):51-63. doi: 10.1007/s11259-009-9332-2. Epub 2009 Dec 23.
There is an on-going need to identify medications suitable for the long-term treatment of canine atopic dermatitis (CAD). Masitinib mesilate is a potent and selective tyrosine kinase inhibitor of the c-KIT receptor. A strong relationship exists between the SCF/c-KIT pathway and pathogenesis of CAD, suggesting that masitinib may potentially fulfil the above role. This study reports on an uncontrolled pilot study of masitinib in CAD. Masitinib was administered orally to 11 dogs at a mean dose of 11.0 +/- 1.83 mg/kg/day (free base) for 28 days. Treatment response was assessed by evolution of clinical appearance according to a modified version of the Canine Atopic Dermatitis Extent and Severity Index (mCADESI), pruritus scale and surface area of lesions. Masitinib improved CAD with a mean reduction in mCADESI of 50.7 +/- 29.8% (95% C.I. = 29.4-72.0; p = 0.0004) at day 28 relative to baseline, with 8/10, 8/10 and 4/10 dogs showing improvement of >or=33%, >or=40% and >or=50%, respectively. Improvement was further evidenced by a decrease in pruritus score and the surface area of lesions. No serious or severe adverse events occurred during this trial, although 6/11 dogs presented with mild to moderate treatment related adverse events. There is sufficient compelling evidence to warrant further investigation.
目前仍需要确定适合长期治疗犬过敏性皮炎 (CAD) 的药物。马替尼酸甲是一种有效的、选择性的 c-KIT 受体酪氨酸激酶抑制剂。SCF/c-KIT 途径与 CAD 的发病机制之间存在密切关系，这表明马替尼可能具有潜在的作用。本研究报告了马替尼治疗 CAD 的一项非对照性初步研究。马替尼以 11.0 ± 1.83 mg/kg/天（游离碱）的平均剂量口服给予 11 只狗，持续 28 天。通过改良的犬过敏性皮炎严重程度指数（mCADESI）、瘙痒评分和病变面积的临床外观变化评估治疗反应。马替尼改善了 CAD，与基线相比，第 28 天 mCADESI 平均降低 50.7 ± 29.8%（95%CI=29.4-72.0；p=0.0004），8/10、8/10 和 4/10 只狗的改善分别>33%、>40%和>50%。瘙痒评分和病变面积的降低进一步证实了改善。在这项试验中没有发生严重或严重的不良事件，但 6/11 只狗出现了轻度至中度与治疗相关的不良事件。有充分的证据表明需要进一步研究。
